UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Non-coding RNA in rhabdomyosarcoma progression and metastasis

Frontiers in oncology, 2022-08, Vol.12, p.971174

2022

Volltextzugriff (PDF)

CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome

Proceedings of the National Academy of Sciences - PNAS, 2013-11, Vol.110 (48), p.19525-19530

2013

Volltextzugriff (PDF)

Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer

International journal of molecular sciences, 2019-06, Vol.20 (11), p.2773

2019

Volltextzugriff (PDF)

Editorial: Impact of Cancer Plasticity on Drug Resistance and Treatment in Solid Tumors

Frontiers in oncology, 2020-10, Vol.10, p.596963-596963

2020

Volltextzugriff (PDF)

The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice

Frontiers in pharmacology, 2019-06, Vol.10, p.667-667

2019

Volltextzugriff (PDF)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX ® Recurrence Score in ER-Positive Invasive Breast Cancers

Frontiers in pharmacology, 2019-05, Vol.10, p.524-524

2019

Volltextzugriff (PDF)

Editorial: Novel Targets and Biomarkers in Solid Tumors

Frontiers in pharmacology, 2019-07, Vol.10, p.828-828

2019

Volltextzugriff (PDF)

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer

Frontiers in oncology, 2021-07, Vol.11, p.647269-647269

2021

Volltextzugriff (PDF)

mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels

Cancer science, 2008-10, Vol.99 (10), p.1992-2003

2008

Volltextzugriff (PDF)

Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay

Frontiers in oncology, 2020-05, Vol.10, p.712-712

2020

Volltextzugriff (PDF)

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

Frontiers in pharmacology, 2019, Vol.9, p.1581-1581

2019

Volltextzugriff (PDF)

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

Molecular cancer, 2010-11, Vol.9 (1), p.291-291, Article 291

2010

Volltextzugriff (PDF)

Environmental pollutants-dependent molecular pathways and carcinogenesis

Biodiscovery, 2019-02, Vol.22, p.464-30

2019

Volltextzugriff (PDF)

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer

Journal of molecular endocrinology, 2009-02, Vol.42 (2), p.87-103

2009

Volltextzugriff (PDF)

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

Breast cancer research : BCR, 2015-01, Vol.17 (1), p.13-13, Article 13

2015

Volltextzugriff (PDF)

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients

Recent patents on anti-cancer drug discovery, 2010-01, Vol.5 (1), p.29-57

2010

Volltextzugriff (PDF)

ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial―Mesenchymal Transition and Invasion

Cancer research (Chicago, Ill.), 2012-07, Vol.72 (14), p.3593-3606

2012

Volltextzugriff (PDF)

Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling

Cell death and differentiation, 2017-01, Vol.24 (1), p.155-166

2017

Volltextzugriff (PDF)

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone

The Journal of pathology, 2017-05, Vol.242 (1), p.73-89

2017

Volltextzugriff (PDF)

Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma

Cancers, 2024-05, Vol.16 (9), p.1652

2024

Volltextzugriff (PDF)

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

International journal of cancer, 2010-01, Vol.126 (2), p.545-562

2010

Volltextzugriff (PDF)

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

Oncotarget, 2015-12, Vol.6 (39), p.41566-41581

2015

Volltextzugriff (PDF)

The Intricate Interplay between the ZNF217 Oncogene and Epigenetic Processes Shapes Tumor Progression

Cancers, 2022-12, Vol.14 (24), p.6043

2022

Volltextzugriff (PDF)

LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Cancer research (Chicago, Ill.), 2016-06, Vol.76 (12), p.3541-3552

2016

Volltextzugriff (PDF)

Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor

International journal of cancer, 2013-10, Vol.133 (7), p.1589-1602

2013

Volltextzugriff (PDF)

1 – 25 von 522

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(403)
Mit Volltextzugriff
(478)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Non-coding RNA in rhabdomyosarcoma progression and metastasis

CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome

Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer

Editorial: Impact of Cancer Plasticity on Drug Resistance and Treatment in Solid Tumors

The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX ® Recurrence Score in ER-Positive Invasive Breast Cancers

Editorial: Novel Targets and Biomarkers in Solid Tumors

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer

mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels

Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

Environmental pollutants-dependent molecular pathways and carcinogenesis

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients

ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial―Mesenchymal Transition and Invasion

Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling

The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone

Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

The Intricate Interplay between the ZNF217 Oncogene and Epigenetic Processes Shapes Tumor Progression

LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor

Suchergebnisse filtern